Tumour node metastasis staging of bladder cancer: prognosis versus pitfalls

Current Opinion in Urology
Nadine T GaisaRuth Knüchel

Abstract

The WHO classification of urothelial cancer in 2004 has made changes based on the insights of molecular genetics, indicating bladder cancer with entities that are genetically stable versus those that are genetically instable. Seen as work in progress, the need of further validation is obvious. Clinical studies based on solid histological diagnosis are as necessary as the definition of more molecular features of bladder cancer. Solid histological diagnosis includes sufficient clinical information and adequate tissue processing. This combined with molecular data will lead to a more clear-cut distinction between benign and malignant and possibly to another change in terminology with higher concordance to other epithelial tumours. Whereas the identification of FGFR3 mutations has led to a better distinction of at least two pathways of urothelial carcinogenesis, additional multiparametric approaches may help improve the still inadequate search for urine and blood markers indicative of bladder cancer and/or its progression. Proteomic profiling, sets of epigenetic markers, and micro RNAs will be given as examples. Recent data mainly support the concept of the WHO 2004 classification of bladder cancer. We are optimistic that an even mo...Continue Reading

References

May 3, 2005·International Journal of Surgical Pathology·Rodolfo Montironi, Antonio Lopez-Beltran
Jun 10, 2005·Nature·Lin HeScott M Hammond
Oct 2, 2007·Journal of Proteome Research·Esteban Orenes-PiñeroMarta Sánchez-Carbayo
Oct 24, 2007·European Urology·Jesus Fernandez-GomezUNKNOWN Club Urológico Español de Tratamiento Oncológico (CUETO)
Mar 28, 2008·Urologic Oncology·Peter C BlackColin P N Dinney
Sep 4, 2008·Pediatric Transplantation·Tara K Sigdel, Minnie M Sarwal
Oct 3, 2008·Cancer Research·Thales PapagiannakopoulosKenneth S Kosik
Mar 14, 2009·European Urology·Kristina SchwambornCorinna Henkel
Sep 29, 2009·Molecular & Cellular Proteomics : MCP·José M A MoreiraIrina Gromova
Oct 22, 2009·Cancer Research·James W F CattoFreddie C Hamdy
Jan 9, 2010·Pathology International·Hiroshi MiyamotoJonathan I Epstein
Jan 12, 2010·Scandinavian Journal of Urology and Nephrology·Ranveig RøtterudKristin A Taskén

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.